Prochem Laboratories Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.57 M
- Company Age 35 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Profit Growth 86.06%
- Ebitda 86.46%
- Net Worth -2.30%
- Total Assets -0.42%
About Prochem Laboratories
Prochem Laboratories Pvt. Ltd. (PLPL) is a Private Limited Indian Non-Government Company incorporated in India on 02 August 1989 and has a history of 35 years and six months. Its registered office is in Indore, Madhya Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.57 M, as per Ministry of Corporate Affairs (MCA) records.
Mahesh Badlani and Usha Badlani serve as directors at the Company.
Company Details
-
Location
Indore, Madhya Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232MP1989PTC005391
-
Company No.
005391
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
02 Aug 1989
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Prochem Laboratories?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mahesh Badlani
|
Director | 02-Aug-1989 | Current |
|
Usha Badlani
|
Director | 09-Mar-1992 | Current |
Financial Performance of Prochem Laboratories.
Prochem Laboratories Pvt. Ltd., for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 86.06% increase in profit. The company's net worth dipped by a decrease of 2.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Prochem Laboratories?
In 2023, Prochem Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Pure Pharma LimitedMahesh Badlani is a mutual person
-
Prochem Pharmaceuticals Private LimitedMahesh Badlani is a mutual person
-
Jpbee Investments Pvt Ltd N
Mahesh Badlani and Usha Badlani are mutual person
-
Promed Laboratories Private Limited
Mahesh Badlani is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Prochem Laboratories?
Unlock and access historical data on people associated with Prochem Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Prochem Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Prochem Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
